Clinical Trials Browser

Completed × spartalizumab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

48 enrolled

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06676293 2024-11-07

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Phase NA Completed

8 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

122 enrolled 28 charts

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Clinical Trials

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

IT-01

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma